Sponsor or institution

Clinical trials and research at EMD Serono

• 8Clinical trials
• 30Countries

Newest trials

All recruiting trials (8)

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• M7437 (anti-Ly6E exatecan antibody–drug conjugate) for advanced solid tumors with Ly6E expression

  This trial will test M7437, an antibody–drug conjugate that targets Ly6E and delivers a topoisomerase I inhibitor, to see if it is safe and helps people with advanced solid tumors that express Ly6E.

  Recruiting at 7 sites Phase 1 EMD Serono · New Haven, Connecticut and 8 other locations · NCT07360314

• Enpatoran for cutaneous lupus with or without systemic disease (ELOWEN-2)

  This 24-week study will test whether enpatoran tablets can improve active skin symptoms in adults with cutaneous lupus, with or without systemic lupus.

  Recruiting at 70 sites Phase 3 EMD Serono · Upland, California and 69 other locations · NCT07355218

• Enpatoran for adults with skin lupus, with or without systemic disease

  This 24-week test will see if enpatoran tablets reduce active skin lesions in adults with cutaneous lupus, with or without systemic lupus.

  Recruiting at 74 sites Phase 3 EMD Serono · Los Angeles, California and 73 other locations · NCT07332481

• M0324 alone or with pembrolizumab or mFOLFIRINOX chemotherapy for selected advanced solid tumors

  This trial tests whether the experimental drug M0324, given alone or with pembrolizumab or mFOLFIRINOX chemotherapy, is safe and shows early signs of benefit for people with advanced solid tumors that overexpress MUC-1.

  Recruiting at 5 sites Phase 1 EMD Serono · New Haven, Connecticut and 4 other locations · NCT07166601

• M3554 treatment for advanced solid tumors

  This study is testing a new treatment called M3554 to see if it can help people with advanced solid tumors, like certain types of sarcomas and glioblastomas, who haven't had success with other treatments.

  Recruiting at 9 sites Phase 1 EMD Serono · Boston, Massachusetts and 10 other locations · NCT06641908

• Registry for patients with advanced non-small cell lung cancer and specific genetic alterations

  This study is collecting information from patients with advanced lung cancer who have a specific genetic change to see how they respond to different treatments over time.

  Recruiting at 73 sites EMD Serono · Fort Lauderdale, Florida and 79 other locations · NCT05376891

Quick answers

How many clinical trials run by EMD Serono are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (8 trials), Belgium (5 trials), Canada (5 trials), Spain (5 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →